(Q37437162)

20 August 2017

1 reference

title

Novel pharmacotherapies to abrogate postinfarction ventricular remodeling (English)

1 reference

20 August 2017

0 references

Gerald W Dorn

1

1 reference

PubMed ID

19352332

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

Nature Reviews Cardiology

20 August 2017

1 reference

20 August 2017

6

1 reference

20 August 2017

4

1 reference

20 August 2017

283-291

1 reference

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications

20 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Left ventricular size after acute myocardial infarction. Serial changes and their prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Endothelium-dependent vasodilation is attenuated in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

beta-adrenergic receptor blockade in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

A novel protective effect of erythropoietin in the infarcted heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Myocardial reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Renin inhibitors, clinical experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarctio

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

AT1 receptor mRNA antisense normalizes enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Catecholamines, cardiac beta-adrenergic receptors, and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

The β-adrenergic receptor kinase in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Gene therapy in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Expression of a beta-adrenergic receptor kinase inhibitor reverses dysfunction in failing cardiomyocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Effects of two Gbetagamma-binding proteins--N-terminally truncated phosducin and beta-adrenergic receptor kinase C terminus (betaARKct)--in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Erythropoietin as an antiapoptotic, tissue-protective cytokine.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Cellular protection by erythropoietin: new therapeutic implications?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Erythropoietin: ready for prime-time cardioprotection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Erythropoietin Induces Neovascularization and Improves Cardiac Function in Rats With Heart Failure After Myocardial Infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

A Single Bolus of a Long-acting Erythropoietin Analogue Darbepoetin Alfa in Patients with Acute Myocardial Infarction: A Randomized Feasibility and Safety Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Effect of EPO administration on myocardial infarct size in patients with non-STE acute coronary syndromes; results from a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Mitochondrial death protein Nix is induced in cardiac hypertrophy and triggers apoptotic cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Inhibition of ischemic cardiomyocyte apoptosis through targeted ablation of Bnip3 restrains postinfarction remodeling in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2009.12

Aldosterone biosynthesis in the rat brain.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19352332

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Endoplasmic reticulum-mitochondria crosstalk in NIX-mediated murine cell death

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19352332

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Gu

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19352332

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCARDIO.2009.12

1 reference

20 August 2017

1 reference

PubMed ID

19352332